TY - JOUR
T1 - TLR2 Dimerization Blockade Allows Generation of Homeostatic Intestinal Macrophages under Acute Colitis Challenge
AU - Gross-Vered, Mor
AU - Shmuel-Galia, Liraz
AU - Zarmi, Batya
AU - Humphries, Fiachra
AU - Thaiss, Christoph
AU - Salame, Tomer-Meir
AU - David, Eyal
AU - Chappell-Maor, Louise
AU - Fitzgerald, Katherine A.
AU - Shai, Yechiel
AU - Jung, Steffen
N1 - We thank all members of the Shai and Jung laboratory for helpful discussion. We further thank the staff of the Weizmann Animal facility, FACS facility, and Israel National Center for Personalized Medicine for expert advice as well as Drs. Udi Zigmond Dan Blat and Ran Afik for help in the colonoscopy, Dr. Reinat Nevo for help with colonoscopy analysis, and Dr. Ron Rotkopf for performing the statistics. This work was supported by grants from the Binational Science Foundation, the Israeli Government in the frame of the Kamin program, and a research grant from the Roland N. Karlen Foundation, all to the Jung laboratory. Y.S. is the incumbent Harold S. and Harriet B. Brady Professorial Chair in Cancer Research, and his laboratory was supported by the Helmsley Trust grant, Israel Science Foundation Grants 1409/12 and 1357/17, and the Pasteur Weizmann Foundation.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Recruited blood monocytes contribute to the establishment, perpetuation, and resolution of tissue inflammation. Specifically, in the inflamed intestine, monocyte ablation was shown to ameliorate colitis scores in preclinical animal models. However, the majority of intestinal macrophages that seed the healthy gut are also monocyte derived. Monocyte ablation aimed to curb inflammation would therefore likely interfere with intestinal homeostasis. In this study, we used a TLR2 trans-membrane peptide that blocks TLR2 dimerization that is critical for TLR2/1 and TLR2/6 heterodimer signaling to blunt inflammation in a murine colitis model. We show that although the TLR2 peptide treatment ameliorated colitis, it allowed recruited monocytes to give rise to macrophages that lack the detrimental proinflammatory gene signature and reduced potentially damaging neutrophil infiltrates. Finally, we demonstrate TLR blocking activity of the peptide on in vitro cultured human monocyte-derived macrophages. Collectively, we provide a significantly improved anti-inflammatory TLR2 peptide and critical insights in its mechanism of action toward future potential use in the clinic.
AB - Recruited blood monocytes contribute to the establishment, perpetuation, and resolution of tissue inflammation. Specifically, in the inflamed intestine, monocyte ablation was shown to ameliorate colitis scores in preclinical animal models. However, the majority of intestinal macrophages that seed the healthy gut are also monocyte derived. Monocyte ablation aimed to curb inflammation would therefore likely interfere with intestinal homeostasis. In this study, we used a TLR2 trans-membrane peptide that blocks TLR2 dimerization that is critical for TLR2/1 and TLR2/6 heterodimer signaling to blunt inflammation in a murine colitis model. We show that although the TLR2 peptide treatment ameliorated colitis, it allowed recruited monocytes to give rise to macrophages that lack the detrimental proinflammatory gene signature and reduced potentially damaging neutrophil infiltrates. Finally, we demonstrate TLR blocking activity of the peptide on in vitro cultured human monocyte-derived macrophages. Collectively, we provide a significantly improved anti-inflammatory TLR2 peptide and critical insights in its mechanism of action toward future potential use in the clinic.
UR - http://www.scopus.com/inward/record.url?scp=85078549976&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1900470
DO - 10.4049/jimmunol.1900470
M3 - مقالة
SN - 0022-1767
VL - 204
SP - 707
EP - 717
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -